Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma

SIMPLE SUMMARY: Survival of patients with multiple myeloma continues to improve over time in parallel with the development of new treatments. The combination of novel agents in the first-line setting appears to be the main factor driving improvement, resulting in overall survival (OS) of more than 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Puertas, Borja, González-Calle, Verónica, Sobejano-Fuertes, Eduardo, Escalante, Fernando, Queizán, José A., Bárez, Abelardo, Labrador, Jorge, Alonso-Alonso, José María, García de Coca, Alfonso, Cantalapiedra, Alberto, Villaescusa, Teresa, Aguilar-Franco, Carlos, Alejo-Alonso, Elena, Rey-Bua, Beatriz, López-Corral, Lucía, García-Sanz, Ramón, Puig, Noemi, Gutiérrez, Norma C., Mateos, María-Victoria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000382/
https://www.ncbi.nlm.nih.gov/pubmed/36900349
http://dx.doi.org/10.3390/cancers15051558

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10000382/
https://www.ncbi.nlm.nih.gov/pubmed/36900349
http://dx.doi.org/10.3390/cancers15051558

Ejemplares similares